<div><div></div><div><span><p><strong><span>Structure Therapeutics appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026.</span></strong></p><div><table><tbody><tr><td><span>Individual</span></td><td><span>Matthew Lang</span></td></tr><tr><td><span>Role</span></td><td><span>Chief Operating Officer and General Counsel</span></td></tr><tr><td><span>Type of Change</span></td><td><span>Appointed</span></td></tr><tr><td><span>Effective Date</span></td><td><span>April 15, 2026</span></td></tr><tr><td><span>Reason</span></td><td><span>Not disclosed</span></td></tr><tr><td><span>Replacement Info</span></td><td><span>Not disclosed</span></td></tr><tr><td><span>Background Details</span></td><td><span>Previously Chief Legal Officer &amp; Corporate Secretary at Metsera (Apr 2025–Feb 2026); CBO &amp; Chief Legal Officer at Lyell (Jul 2023–Apr 2025); various executive legal roles at Myovant (2017–2023); VP at Gilead (2009–2017); attorney at Dechert (2003–2009). JD, Univ. of Pennsylvania Law School.</span></td></tr><tr><td><span>Board/Committee Role Changes</span></td><td><span>Not disclosed</span></td></tr></tbody></table></div><p><span>Original SEC Filing: </span>Structure Therapeutics Inc. [ GPCR ] - 8-K - Apr. 15, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

GPCR

<p>Structure Therapeutics has appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. Lang previously held roles such as Chief Legal Officer at Metsera and CBO at Lyell, among others. The reason for his appointment and replacement information have not been disclosed. This announcement is documented in an SEC filing.</p>

TradingView

Structure Therapeutics

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

VG Health

SPDR S&P Biotech

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

VanEck Biotech ETF

Metsera

Lyell Immunopharma

Gilead Sciences

Structure Therapeutics appoints Matthew Lang as COO and General Counsel